Skip to main content

Advertisement

SpringerLink
Log in

Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells

  • Original Paper
  • Published:
Cellular Oncology Aims and scope Submit manuscript

Abstract

Purpose

The 4,5-diarylimidazole brimamin is an analog of the natural vascular-disrupting agent combretastatin A-4 (CA-4) with improved water solubility, tolerance by animals and efficacy in multidrug-resistant tumors. Here, we aimed at identifying the major mechanisms underlying the in vitro and in vivo actions of brimamin on endothelial and carcinoma cells, including vascularization.

Methods

The contribution of specific signaling kinases to the effects of brimamin on cytoskeleton organization and the viability and differentiation of endothelial cells was assessed by MTT and tube formation assays in the presence or absence of specific kinase inhibitors. Changes in DNA affinity and expression of NF-κB in endothelial and carcinoma-derived cells and their solid tumors (xenografts) treated with brimamin were ascertained by electrophoretic mobility shift assays and Western blotting. The anti-vascular effect of brimamin in solid tumors was verified by CD31 immunostaining.

Results

We found that brimamin can inhibit tubulin polymerization and cause a reorganization of F-actin in Ea.hy926 endothelial cells. Its inhibitory effect on tube formation was found to depend on functional Rho kinase and JNK. JNK inhibition was found to suppress the induction of endothelial cell apoptosis by brimamin. In CA-4-refractory human BxPC-3 pancreas carcinoma-derived and triple-negative MDA-MB-231 breast carcinoma-derived cells brimamin was found to inhibit growth and to induce apoptosis at low nanomolar concentrations by blocking NF-κB activation in a dose-dependent manner. Brimamin was also found to reduce the in vivo growth rate and vascularization of MDA-MB-231 xenografts in mice. Residual tumor cells of these treated xenografts showed a relatively low expression of the p65 subunit of NF-κB.

Conclusions

Our data indicate that cellular JNK and Rho kinase activities are crucial for the cytotoxic and cytoskeleton reorganizing effects of brimamin on endothelial cells. In addition, we found that in resistant carcinoma cells and xenografts brimamin can induce down-regulation of anti-apoptotic NF-κB expression and signaling. Its chemical properties and efficacy against clinically relevant cancer entities make brimamin a promising candidate vascular-disrupting agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. G. Pettit, S. Singh, E. Hamel, C. Lin, D. Alberts, D. Garcia-Kendall, Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45, 209–211 (1989)

    Article  CAS  PubMed  Google Scholar 

  2. C.J. Mooney, G. Nagaiah, P. Fu, J.K. Wasman, M.M. Cooney, P.S. Savvides, J.A. Bokar, A. Dowlati, D. Wang, S.S. Agarwala, A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19, 233–240 (2009)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. G.J. Rustin, G. Shreeves, P.D. Nathan, A. Gaya, T.S. Ganesan, D. Wang, J. Boxall, L. Poupard, D.J. Chaplin, M.R.L. Stratford, J. Balkissoon, M. Zweifel, A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br. J. Cancer 102, 1355–1360 (2010)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. G.C. Tron, T. Pirali, G. Sorba, F. Pagliai, S. Busacca, A.A. Genazzani, Medicinal chemistry of combretastatin A4: present and future directions. J. Med. Chem. 49, 3033–3044 (2006)

    Article  CAS  PubMed  Google Scholar 

  5. S.E. Holwell, P.A. Cooper, M.J. Thompson, G.R. Pettit, L.W. Lippert 3rd, S.W. Martin, M.C. Bibby, Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Res. 22, 3933–3940 (2002)

    CAS  PubMed  Google Scholar 

  6. L.K. Folkes, M. Christlieb, E. Madej, M.R.L. Stratford, P. Wardman, Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals. Chem. Res. Toxicol. 20, 1885–1894 (2007)

    Article  CAS  PubMed  Google Scholar 

  7. G.R. Pettit, M.R. Rhodes, D.L. Herald, D.J. Chaplin, M.R. Stratford, E. Hamel, R.K. Pettit, J.C. Chapuis, D. Oliva, Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug. Anticancer Drug Des. 13, 981–993 (1998)

    CAS  PubMed  Google Scholar 

  8. G.R. Pettit, B.E. Toki, D.L. Herald, M.R. Boyd, E. Hamel, R.K. Pettit, J.C. Chapuis, Antineoplastic agents. 410. Asymmetric hydroxylation of trans-combretastatin A-4. J. Med. Chem. 42, 1459–1465 (1999)

    Article  CAS  PubMed  Google Scholar 

  9. L. Wang, K.W. Woods, Q. Li, K.J. Barr, R.W. McCroskey, S.M. Hannick, L. Gherke, R.B. Credo, Y.-H. Hui, K. Marsh, R. Warner, J.Y. Lee, N. Zielinski-Mozng, D. Frost, S.H. Rosenberg, H.L. Sham, Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure − activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J. Med. Chem. 45, 1697–1711 (2002)

    Article  CAS  PubMed  Google Scholar 

  10. R. Schobert, B. Biersack, A. Dietrich, K. Effenberger, S. Knauer, T. Mueller, 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model. J. Med. Chem. 53, 6595–6602 (2010)

    Article  CAS  PubMed  Google Scholar 

  11. K. Mahal, B. Biersack, H. Caysa, R. Schobert, T. Mueller, Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation. Investig. New Drugs 33, 541–554 (2015)

    Article  CAS  Google Scholar 

  12. C. Kanthou, The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99, 2060–2069 (2002)

    Article  CAS  PubMed  Google Scholar 

  13. B.B. Aggarwal, S. Shishodia, S.K. Sandur, M.K. Pandey, G. Sethi, Inflammation and cancer: how hot is the link? Biochem. Pharmacol. 72, 1605–1621 (2006)

    Article  CAS  PubMed  Google Scholar 

  14. A. Ahmad, S. Banerjee, Z. Wang, D. Kong, F.H. Sarkar, Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-κB and Bcl-2. J. Cell. Biochem. 105, 1461–1471 (2008)

    Article  CAS  PubMed  Google Scholar 

  15. S. Ali, A. Ahmad, S. Banerjee, S. Padhye, K. Dominiak, J.M. Schaffert, Z. Wang, P.A. Philip, F.H. Sarkar, Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 70, 3606–3617 (2010)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Y. He, H. Xu, L. Liang, Z. Zhan, X. Yang, X. Yu, Y. Ye, L. Sun, Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis. Arthritis Rheum. 58, 3366–3376 (2008)

    Article  CAS  PubMed  Google Scholar 

  17. H. Shimada, L.E. Rajagopalan, Rho kinase-2 activation in human endothelial cells drives lysophosphatidic acid-mediated expression of cell adhesion molecules via NF-kappaB p65. J. Biol. Chem. 285, 12536–12542 (2010)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. S. Shimizu, M. Tahara, S. Ogata, K. Hashimoto, K. Morishige, K. Tasaka, Y. Murata, Involvement of nuclear factor-kappaB activation through RhoA/Rho-kinase pathway in LPS-induced IL-8 production in human cervical stromal cells. Mol. Hum. Reprod. 13, 181–187 (2007)

    Article  CAS  PubMed  Google Scholar 

  19. G.G. Mackenzie, C.L. Keen, P.I. Oteiza, Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc. J. Neurochem. 99, 402–415 (2006)

    Article  CAS  PubMed  Google Scholar 

  20. V. Bourgarel-Rey, S. Vallee, O. Rimet, S. Champion, D. Braguer, A. Desobry, C. Briand, Y. Barra, Involvement of nuclear factor kappaB in c-Myc induction by tubulin polymerization inhibitors. Mol. Pharmacol. 59, 1165–1170 (2001)

    CAS  PubMed  Google Scholar 

  21. T.F. Hansen, B.S. Nielsen, A. Jakobsen, F.B. Sorensen, Visualising and quantifying angiogenesis in metastatic colorectal cancer. A comparison of methods and their predictive value for chemotherapy response. Cell. Oncol. 36, 341–350 (2013)

    Article  CAS  Google Scholar 

  22. B. Pula, M. Olbromski, A. Wojnar, A. Gomulkiewicz, W. Witkiewicz, M. Ugorski, P. Dziegiel, M. Podhorska-Okolow, Impact of SOX18 expression in cancer cells and vessels on the outcome of invasive ductal breast carcinoma. Cell. Oncol. 36, 469–483 (2013)

    Article  CAS  Google Scholar 

  23. A.W. Schüttelkopf, D.M.F. van Aalten, PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355–1363 (2004)

    Article  PubMed  Google Scholar 

  24. O. Trott, A.J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455–461 (2009)

    Google Scholar 

  25. J. Gasteiger, M. Marsili, Iterative partial equalization of orbital electronegativity – a rapid access to atomic charges. Tetrahedron 36, 3219–3228 (1980)

    Article  CAS  Google Scholar 

  26. G.L. Warren, C.W. Andrews, A.-M. Capelli, B. Clarke, J. LaLonde, M.H. Lambert, M. Lindvall, N. Nevins, S.F. Semus, S. Senger, G. Tedesco, I.D. Wall, J.M. Woolven, C.E. Peishoff, M.S. Head, A critical assessment of docking programs and scoring functions. J. Med. Chem. 49, 5912–5931 (2006)

    Article  CAS  PubMed  Google Scholar 

  27. W. DeLano, The PyMOL molecular graphics system (DeLano Sci, LLC San Carlos CA, 2003)

    Google Scholar 

  28. K. Mahal, S. Schruefer, G. Steinemann, F. Rausch, R. Schobert, M. Höpfner, B. Biersack, Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents. Cancer Chemother. Pharmacol. 75, 691–700 (2015)

    Article  CAS  PubMed  Google Scholar 

  29. K. Mahal, M. Resch, R. Ficner, R. Schobert, B. Biersack, T. Mueller, Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels. ChemMedChem 9, 847–854 (2014)

    Article  CAS  PubMed  Google Scholar 

  30. G.M. Tozer, C. Kanthou, B.C. Baguley, Disrupting tumour blood vessels. Nat. Rev. Cancer 5, 423–435 (2005)

    Article  CAS  PubMed  Google Scholar 

  31. B. Biersack, K. Effenberger, R. Schobert, M. Ocker, Oxazole-bridged combretastatin a analogues with improved anticancer properties. ChemMedChem 5, 420–427 (2010)

    Article  CAS  PubMed  Google Scholar 

  32. S. Ali, Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol. Cancer Ther. 4, 1943–1951 (2005)

    Article  CAS  PubMed  Google Scholar 

  33. R.B.G. Ravelli, B. Gigant, P.A. Curmi, I. Jourdain, S. Lachkar, A. Sobel, M. Knossow, Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428, 198–202 (2004)

    Article  CAS  PubMed  Google Scholar 

  34. M. Botta, S. Forli, M. Magnani, F. Manetti, Molecular modeling approaches to study the binding mode on tubulin of microtubule destabilizing and stabilizing agents. Top. Curr. Chem. 286, 279–328 (2009)

    Article  CAS  PubMed  Google Scholar 

  35. C. Kanthou, G.M. Tozer, Tumour targeting by microtubule-depolymerising vascular disrupting agents. Expert Opin. Ther. Targets 11, 1443–1457 (2007)

    Article  CAS  PubMed  Google Scholar 

  36. H. Quan, Y. Xu, L. Lou, p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. Int. J. Cancer 122, 1730–1737 (2007)

    Article  Google Scholar 

  37. M. Fan, L. Du, A. Stone, K. Gilbert, T. Chambers, Modulation of mitogen-activated protein kinases and phosphorylation of Bcl-2 by vinblastine represent persistent forms of normal fluctuations at G2-M. Cancer Res. 60, 6403–6407 (2000)

    CAS  PubMed  Google Scholar 

  38. C. Kanthou, G.M. Tozer, Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int. J. Exp. Pathol. 90, 284–294 (2009)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. M. Chrzanowska-Wodnicka, K. Burridge, Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J. Cell Biol. 133, 1403–1415 (1996)

    Article  CAS  PubMed  Google Scholar 

  40. L.J. Williams, D. Mukherjee, M. Fisher, C.C. Reyes-Aldasoro, S. Akerman, C. Kanthou, G.M. Tozer, An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate: Rho kinase and tumour vascular targeting. Br. J. Pharmacol. 171, 4902–4913 (2014)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. A. Arlt, A. Gehrz, S. Müerköster, J. Vorndamm, M.-L. Kruse, U.R. Fölsch, H. Schäfer, Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22, 3243–3251 (2003)

    Article  CAS  PubMed  Google Scholar 

  42. M. Graupera, J. Guillermet-Guibert, L.C. Foukas, L.-K. Phng, R.J. Cain, A. Salpekar, W. Pearce, S. Meek, J. Millan, P.R. Cutillas, A.J.H. Smith, A.J. Ridley, C. Ruhrberg, H. Gerhardt, B. Vanhaesebroeck, Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration. Nature 453, 662–666 (2008)

    Article  CAS  PubMed  Google Scholar 

  43. J. Karar, A. Maity, PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci. 4, 51 (2011)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. G. Rajashekhar, M. Kamocka, A. Marin, M.A. Suckow, W.R. Wolter, S. Badve, A.R. Sanjeevaiah, K. Pumiglia, E. Rosen, M. Clauss, Pro-inflammatory angiogenesis is mediated by p38 MAP kinase. J. Cell. Physiol. 226, 800–808 (2011)

    Article  CAS  PubMed  Google Scholar 

  45. M. Kelkel, C. Cerella, F. Mack, T. Schneider, C. Jacob, M. Schumacher, M. Dicato, M. Diederich, ROS-independent JNK activation and multisite phosphorylation of Bcl-2 link diallyl tetrasulfide-induced mitotic arrest to apoptosis. Carcinogenesis 33, 2162–2171 (2012)

    Article  CAS  PubMed  Google Scholar 

  46. J.D. Orth, A. Loewer, G. Lahav, T.J. Mitchison, Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction. Mol. Biol. Cell 23, 567–576 (2012)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. S.P. Tabruyn, A.W. Griffioen, A new role for NF-kappaB in angiogenesis inhibition. Cell Death Differ. 14, 1393–1397 (2007)

    Article  CAS  PubMed  Google Scholar 

  48. S.P. Tabruyn, S. Memet, P. Ave, C. Verhaeghe, K.H. Mayo, I. Struman, J.A. Martial, A.W. Griffioen, NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Mol. Cancer Ther. 8, 2645–2654 (2009)

    Article  CAS  PubMed  Google Scholar 

  49. M. Carr, L.M. Greene, A.J.S. Knox, D.G. Lloyd, D.M. Zisterer, M.J. Meegan, Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects. Eur. J. Med. Chem. 45, 5752–5766 (2010)

    Article  CAS  PubMed  Google Scholar 

  50. H. Wehbe, C.M. Kearney, K.G. Pinney, Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in β-tubulin isotype expression. Anticancer Res. 25, 3865–3870 (2005)

    CAS  PubMed  Google Scholar 

  51. E.C. Tampaki, L. Nakopoulou, A. Tampakis, K. Kontzoglou, W.P. Weber, G. Kouraklis, Nestin involvement in tissue injury and cancer - a potential tumor marker? Cell. Oncol. 37, 305–315 (2014)

    Article  CAS  Google Scholar 

  52. D.O. Moon, M.O. Kim, C.H. Kang, J.D. Lee, Y.H. Choi, G.Y. Kim, JNK inhibitor SP600125 promotes the formation of polymerized tubulin, leading to G2/M phase arrest, endoreduplication, and delayed apoptosis. Exp. Mol. Med. 41, 665–677 (2009)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. A.V. Singh, M. Bandi, N. Raje, P. Richardson, M.A. Palladino, D. Chauhan, K.C. Anderson, A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood 117, 5692–5700 (2011)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. L. Ciani, P.C. Salinas, c-Jun N-terminal kinase (JNK) cooperates with Gsk3β to regulate dishevelled-mediated microtubule stability. BMC Cell Biol. 8, 27 (2007)

    Article  PubMed Central  PubMed  Google Scholar 

  55. D.C.H. Ng, T.T. Zhao, Y.Y.C. Yeap, K.R. Ngoei, M.A. Bogoyevitch, c-Jun N-terminal kinase phosphorylation of stathmin confers protection against cellular stress. J. Biol. Chem. 285, 29001–29013 (2010)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Y.Y. Yip, Y.Y.C. Yeap, M.A. Bogoyevitch, D.C.H. Ng, Differences in c-Jun N-terminal kinase recognition and phosphorylation of closely related stathmin-family members. Biochem. Biophys. Res. Commun. 446, 248–254 (2014)

    Article  CAS  PubMed  Google Scholar 

  57. J.-H. Kim, T.H. Kim, H.S. Kang, J. Ro, H.S. Kim, S. Yoon, SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin. Biochem. Biophys. Res. Commun. 387, 450–455 (2009)

    Article  CAS  PubMed  Google Scholar 

  58. X. Wang, K. Belguise, N. Kersual, K.H. Kirsch, N.D. Mineva, F. Galtier, D. Chalbos, G.E. Sonenshein, Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat. Cell Biol. 9, 470–478 (2007)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. H. Lee, J. Jeon, Y.S. Ryu, J.E. Jeong, S. Shin, T. Zhang, S.W. Kang, J.H. Hong, G.M. Hur, Disruption of microtubules sensitizes the DNA damage-induced apoptosis through inhibiting nuclear factor kappaB (NF-κB) DNA-binding activity. J. Korean Med. Sci. 25, 1574 (2010)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. S. Papa, Linking JNK signaling to NF-kappaB: a key to survival. J. Cell Sci. 117, 5197–5208 (2004)

    Article  CAS  PubMed  Google Scholar 

  61. L. Li, B.B. Aggarwal, S. Shishodia, J. Abbruzzese, R. Kurzrock, Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101, 2351–2362 (2004)

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interests

The authors declare that there are no conflicts of interest.

Author information

Authors and Affiliations

  1. Organic Chemistry Laboratory, University Bayreuth, Universitaetsstrasse 30, 95440, Bayreuth, Germany

    Katharina Mahal, Rainer Schobert & Bernhard Biersack

  2. Karmanos Cancer Institute, Department of Pathology, Wayne State University School of Medicine, 4100 John R. Street, Detroit, 48201, MI, USA

    Aamir Ahmad, Seema Sethi & Fazlul H. Sarkar

  3. Department of Molecular Structural Biology, Georg-August-University Göttingen, Justus-von-Liebig-Weg 11, 37077, Göttingen, Germany

    Marcus Resch & Ralf Ficner

Authors
  1. Katharina Mahal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aamir Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seema Sethi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marcus Resch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ralf Ficner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fazlul H. Sarkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rainer Schobert
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bernhard Biersack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rainer Schobert.

Electronic supplementary material

The online version of this article contains supplementary material (determination of apoptosis in Ea.hy926 endothelial, resistant BxPC-3 pancreas, and MDA-MB-231 breast carcinoma cells; original Western blot images) which is available to authorized users.

ESM 1

(PDF 6051 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mahal, K., Ahmad, A., Sethi, S. et al. Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells. Cell Oncol. 38, 463–478 (2015). https://doi.org/10.1007/s13402-015-0243-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13402-015-0243-7

Keywords

Search

Navigation